Connect with us

Biotech

Encomenda Invests €200,000 to Launch Telemedicine Startup Doctomatic

The fund led by Carlos Blanco and Oriol Juncosa has helped launch this new digital platform, called Doctomatic, for remote management of chronic patients, led by the co-founder of Doctoralia. For its part, Encomenda has been actively involved in other projects linked to the healthcare sector, such as Mediquo.

Published

on

New project in healthcare. The co-founder of Doctoralia and ambassador of the Barcelona Health Hub (BHH), Frederic Llordachs, has launched Doctomatic, a new digital platform for the remote management of chronic patients. The main investor in the project is Encomenda Smart Capital, the fund led by Carlos Blanco and Oriol Juncosa, as Llordachs explained.

Encomenda becomes the lead investor in this new digital health company, whose headquarters are located on Carrer de Sant Antoni Maria Claret in Barcelona. For the moment, the fund has contributed $234,000 (€200,000) to the company, although Llordachs advances that it will receive another $176,000 (€150,000) more in this initial phase.

“I have been insisting for years that the way of managing chronic patients must change and that this must be supported by cost-effective technological support; that is what we are trying to do with Doctomatic,” explained Llordachs.

Read more on the subject and find other important business news with the Born2Invest mobile app.

Encomenda has contributed $234,000 (€200,000) to the Barcelona-based digital health company

For its development, Llordachs has surrounded himself with a team made up of Marcos Bermejo, who had previously worked with him at Doctoralia, and Carmen Pauline Rios, who comes from Limbix, a company specializing in digital therapies for adolescent mental health and which is based in Palo Alto (United States).

Llordachs explained that Doctomatic will not be a tool for all types of patients or all types of healthcare professionals, but is focused on those who are chronic, multi-pathological, often “the most expensive for the healthcare system,” said the executive.

SEE ALSO  Colombia’s cannabis industry insists on dried flower exports

“With our technology we aim to make the patient responsible in the initial phases and create adherence to medication,” says Llordachs, who confesses that they are already starting to work with the first healthcare professionals. Llordachs is co-founder of Doctoralia, a marketplace that connects patients with healthcare specialists.

In addition to being an entrepreneur, he is also an advisor at the Mobile Health Competence Centre in Barcelona (Mobile World Capital Foundation), eHealth director at Aces, member of the eHealth section of the Official College of Doctors of Barcelona (Comb) and since 2012 he has been in charge of Health 2.0 in its Spanish editions.

He holds a degree in Medicine and Surgery and an MBA in Health Management and Marketing from Esade, where he has collaborated with the departments of Business Policy, Marketing and the Entrepreneurship Institute of Esade. His experience in health management includes eight years working in health insurance companies in Spain, in the pharmaceutical industry and five years as medical director of the Cima Clinic in Barcelona.

For its part, Encomenda has been actively involved in other projects linked to the healthcare sector, such as Mediquo. In fact, the fund was one of the main investors in the financing round that this company closed last April, raising $2.7 million (€2.3 million).

__

(Featured image by Tumisu via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.